Results 1 to 10 of about 5,186 (110)

Interplay of Vitamin D and Polymorphisms in Endocrine Disorders and Cancer [PDF]

open access: yesEndocrinology and Metabolism, 2022
Vitamin D has received considerable optimistic attention as a potentially important factor in many pathological states over the past few decades. However, the proportion of the active form of vitamin D metabolites responsible for biological activity is ...
Siva Swapna Kasarla   +3 more
doaj   +1 more source

Sex and Age Influence on Association of CYP450 Polymorphism with Midazolam Levels in Critically Ill Children

open access: yesDiagnostics, 2022
Midazolam is a drug that is metabolized by cytochrome P450 (CYP450) enzymes, particularly CYP3A4 and CYP3A5. The present study aimed to determine the sex and age influence on association of CYP450 polymorphism with midazolam levels in critically ill ...
Carmen Flores-Pérez   +6 more
doaj   +1 more source

A rare complication of coronary vasospasm associated with concomitant use of ergotamine, cobicistat, and darunavir

open access: yesAntiviral Therapy, 2022
Ergotism is a rare cause of peripheral vasoconstriction with varying presentation depending on the affected vessels. Coronary vasospasm is a rare, potentially fatal manifestation of ergotism.
Cheng-En Wu   +3 more
doaj   +1 more source

Gut microbiome modulates tacrolimus pharmacokinetics through the transcriptional regulation of ABCB1

open access: yesMicrobiome, 2023
Background Following solid organ transplantation, tacrolimus (TAC) is an essential drug in the immunosuppressive strategy. Its use constitutes a challenge due to its narrow therapeutic index and its high inter- and intra-pharmacokinetic (PK) variability.
Alexandra L. Degraeve   +7 more
doaj   +1 more source

Identifying cytochrome P450s involved in oxidative metabolism of synthetic cannabinoid N‐(adamantan‐1‐yl)‐1‐(5‐fluoropentyl)‐1H‐indole‐3‐carboxamide (STS‐135)

open access: yesPharmacology Research & Perspectives, 2020
Synthetic cannabinoids (SCBs), designer drugs marketed as legal alternatives to marijuana, act as ligands to cannabinoid receptors; however, they have increased binding affinity and potency, resulting in toxicity symptoms such as cardiovascular incidents,
Sabrina Jones   +6 more
doaj   +1 more source

Auto-Induction Effect of Chloroxoquinoline on the Cytochrome P450 Enzymes of Rats Associated with CYP 3A and 1A. [PDF]

open access: yesPLoS ONE, 2015
To investigate the auto-induction of cytochrome P450 (CYP450) by Chloroxoquinoline (CXL), a novel anticancer drug. Three experiments related to the induction of CYP450 were performed: a) In vitro use of the rat fresh hepatocytes model; b) In vivo ...
Xin Li   +7 more
doaj   +1 more source

Inhibitory Effect of Antituberculosis Drugs on Human Cytochrome P450-Mediated Activities

open access: yesJournal of Pharmacological Sciences, 2004
The potential for drug-drug interactions mediated by the inhibition of cytochrome P-450 (CYP) were concerned during antituberculosis therapy. However, the information regarding human CYP inhibition by antituberculosis drugs is limited to isoniazid.
Yuki Nishimura   +3 more
doaj   +1 more source

Monitoring imatinib plasma concentrations in chronic myeloid leukemia

open access: yesRevista Brasileira de Hematologia e Hemoterapia, 2011
Imatinib has proved to be effective in the treatment of chronic myeloid leukemia, but plasma levels above 1,000 ng/mL must be achieved to optimize activity.
Darlize Hübner Martins   +6 more
doaj   +1 more source

Predictors of Irinotecan Toxicity and Efficacy in Treatment of Metastatic Colorectal Cancer

open access: yesActa Medica, 2012
The colorectal cancer ranks high among the malignant tumours in incidence and mortality and irinotecan is standardly used in palliative treatment of metastatic disease in every therapeutic line.
Adam Paulík   +2 more
doaj   +1 more source

Eficácia terapêutica do Tacrolimo em pacientes pós-transplante hepático com polimorfismos genéticos do citocromo P450 3A5 (CYP3A5)

open access: yesRevista do Colégio Brasileiro de Cirurgiões
RESUMO Os polimorfismos genéticos do CYP3A5 têm sido apontados enquanto fatores influenciadores na eficácia farmacológica com tacrolimo em pacientes em terapia imunossupressora no pós-transplante hepático.
Lucas Soares Bezerra   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy